Nothing Special   »   [go: up one dir, main page]

HRP20171208T1 - Novi derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti koje se baziraju na ekspresiji cx3cr1 i p40 - Google Patents

Novi derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti koje se baziraju na ekspresiji cx3cr1 i p40 Download PDF

Info

Publication number
HRP20171208T1
HRP20171208T1 HRP20171208TT HRP20171208T HRP20171208T1 HR P20171208 T1 HRP20171208 T1 HR P20171208T1 HR P20171208T T HRP20171208T T HR P20171208TT HR P20171208 T HRP20171208 T HR P20171208T HR P20171208 T1 HRP20171208 T1 HR P20171208T1
Authority
HR
Croatia
Prior art keywords
group
carbon atoms
acid
hydrogen
alkyl group
Prior art date
Application number
HRP20171208TT
Other languages
English (en)
Inventor
Angelo Guglielmotti
Guido Furlotti
Giorgina Mangano
Nicola Cazzolla
Barbara Garofalo
Original Assignee
Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. filed Critical Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A.
Publication of HRP20171208T1 publication Critical patent/HRP20171208T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • AIDS & HIV (AREA)

Claims (15)

1. Spoj, naznačen time, da ima sljedeću formulu (I): [image] u kojoj A može biti -X1- ili -X1-OC(R9)(R10)-, gdje X1 može biti alkil-skupina koja ima od jednoga do pet atoma ugljika, opcijski supstituirana s jednom ili više alkil-skupina koje imaju od jednoga do pet atoma ugljika ili s jednom ili više alkoksi-skupina koje imaju od jednoga do tri atoma ugljika; i R9 i R10, koje mogu biti međusobno identične ili različite, mogu biti vodik, alkil-skupina koja ima od jednoga do pet atoma ugljika ili alkoksi-skupina koja ima od jednoga do tri atoma ugljika; Y je -OH; R1 i R2, koje mogu biti međusobno identične ili različite, mogu biti vodik, alkil-skupina koja ima od jednoga do pet atoma ugljika ili alkoksi-skupina koja ima od jednoga do tri atoma ugljika; R3, R4 i R8, koje mogu biti međusobno identične ili različite, mogu biti vodik, alkil-skupina koja ima od jednoga do pet atoma ugljika, alkoksi-skupina koja ima od jednoga do tri atoma ugljika, atom halogena, -OH, -N(R')(R''), -N(R')COR'', -CN, -CONR'R'', -SO2NR'R'', -SO2R', nitro i trifluorometil; s R' i R'', koje mogu biti međusobno identične ili različite, a predstavljene su vodikom i alkil-skupinom koja ima od jednoga do pet atoma ugljika; R5 može biti vodik, alkil-skupina koja ima od jednoga do pet atoma ugljika, alkoksi-skupina koja ima od jednoga do tri atoma ugljika, atom halogena, -OH, -N(R')(R''), -N(R')COR'', nitro i trifluorometil; ili R5 zajedno s jednom od R6 i R7, tvori prsten koji ima pet ili šest atoma ugljika; s R' i R'', koje mogu biti međusobno identične ili različite, a predstavljene su vodikom i alkil-skupinom koja ima od jednoga do pet atoma ugljika; R6 i R7, koje mogu biti međusobno identične ili različite, mogu biti vodik, alkil-skupina koja ima od jednoga do pet atoma ugljika, ili zajedno tvore skupinu C=O, ili jedna od R6 i R7, zajedno s R5, tvori prsten koji ima pet ili šest atoma ugljika; uz uvjet da kada Y je -OH, tada je A različita od alkil-skupine koja ima jedan atom ugljika, opcijski supstituirana s jednom ili više alkil-skupina koje imaju od jednoga do pet atoma ugljika, ili je alternativno, najmanje jedna od skupina od R1 do R8, različita od vodika.
2. Spoj prema zahtjevu 1, naznačen time, da X1 je alkil-skupina koja ima od jednoga do tri atoma ugljika, opcijski supstituirana s jednom ili više alkil-skupina koje imaju od jednoga do tri atoma ugljika ili s jednom ili više alkoksi-skupina koje imaju od jednoga do dva atoma ugljika.
3. Spoj prema zahtjevu 1, naznačen time, da X1 je izabrana iz skupine koja obuhvaća CH2-skupinu, CH2CH2-skupinu ili C(CH3)2-skupinu, te su R9 i R10, koje mogu biti međusobno identične ili različite, vodik ili CH3-skupina.
4. Spoj prema zahtjevu 1, naznačen time, da je ostatak A izabran iz skupine koja obuhvaća CH2-skupinu, CH2CH2-skupinu, C(CH3)2-skupinu, CH2CH2OCH2-skupinu, CH2CH2OC(CH3)2-skupinu, te CH2CH2CH2OC(CH3)2-skupinu.
5. Spoj prema zahtjevu 1, naznačen time, da su R3, R4 i R8, koje mogu biti međusobno identične ili različite, izabrane iz skupine koju čine atom vodika, alkil-skupina koja ima od jednoga do tri atoma ugljika, alkoksi-skupina koja ima od jednoga do dva atoma ugljika, atom Br, atom Cl ili atom F, OH-skupina, nitro-skupina, trifluorometil-skupina, ili -N(R')(R'')-skupina ili N(R')COR'', -CN, -CONR'R'', -SO2NR'R'', -SO2R', s R' i R'', koje mogu biti međusobno identične ili različite, a predstavljene su atomom vodika i alkil-skupinom koja ima od jednoga do tri atoma ugljika.
6. Spoj prema zahtjevu 1, naznačen time, da R5 je izabrana iz skupine koja obuhvaća atom vodika, alkil-skupinu koja ima od jednoga do tri atoma ugljika, alkoksi-skupinu koja ima od jednoga do dva atoma ugljika, atom halogena, OH-skupinu, ili R5, zajedno s jednim od R6 i R7, tvori prsten koji ima pet ili šest atoma ugljika.
7. Spoj prema zahtjevu 1, naznačen time, da su R6 i R7, koje mogu biti međusobno identične ili različite, izabrane iz skupine koju čine atom vodika, alkil-skupina koja ima od jednoga do tri atoma ugljika, ili zajedno tvore skupinu C=O, ili jedan od R6 i R7, zajedno s R5, tvori prsten koji ima pet ili šest atoma ugljika.
8. Farmaceutski sastav, naznačen time, da obuhvaća spoj formule (I) prema bilo kojem od prethodnih zahtjeva, ili njegovu farmaceutski prihvatljivu sol ili njegov farmaceutski prihvatljiv ester, te najmanje jedan farmaceutski prihvatljiv nosač.
9. Farmaceutski sastav prema zahtjevu 8, naznačen time, da je navedena farmaceutski prihvatljiva sol takva, da je to adicijska sol s fiziološki prikladnim organskim ili mineralnim kiselinama ili lužinama.
10. Farmaceutski sastav prema zahtjevu 9, naznačen time, da su navedene fiziološki prikladne kiseline izabrane iz skupine koju čine klorovodična kiselina, bromovodična kiselina, sumporna kiselina, fosforna kiselina, dušična kiselina, octena kiselina, askorbinska kiselina, benzoeva kiselina, limunska kiselina, fumarna kiselina, mliječna kiselina, maleična kiselina, metansulfonska kiselina, oksalna kiselina, para-toluensulfonska kiselina, benzensulfonska kiselina, sukcinska kiselina, taninska kiselina i vinska kiselina.
11. Farmaceutski sastav prema zahtjevu 9, naznačen time, da su navedene fiziološki prikladne lužine izabrane iz skupine koju čine amonijev hidroksid, kalcijev hidroksid, magnezijev karbonat, natrijev vodikov karbonat, kalijev vodikov karbonat, arginin, betain, kafein, kolin, N,N-dibenziletilendiamin, dietilamin, 2-dietilaminoetanol, 2-dimetilaminoetanol, etanolamin, etilendiamin, N-etilmorfolin, N-etilpiperidin, N-metilglukamin, glukamin, glukozamin, histidin, N-(2-hidroksietil)piperidin, N-(2-hidroksietil)pirolidin, izopropilamin, lizin, metilglukamin, morfolin, piperazin, piperidin, teobromin, trietilamin, trimetilamin, tripropilamin i trometamin.
12. Farmaceutski sastav prema zahtjevu 8, naznačen time, da je navedeni farmaceutski prihvatljiv ester stvoren s fiziološki prikladnim organskim kiselinama ili alkoholima.
13. Farmaceutski sastav prema bilo kojem od zahtjeva 8 do 12, naznačen time, da navedeni sastav obuhvaća stereoizomer ili enantiomer od spoja formule (I), ili od njegove farmaceutski prihvatljive soli, ili od njegovog farmaceutski prihvatljivog estera, ili od njihove mješavine.
14. Farmaceutski sastav prema bilo kojem od zahtjeva 8 do 13, naznačen time, da je navedeni farmaceutski prihvatljiv nosač izabran iz skupine koju čine klizna sredstva, veziva, dezintegratori, punila, razrjeđivači, pojačivači okusa, bojila, fluidizatori, maziva, konzervansi, ovlaživači, apsorbenti i sladila.
15. Spoj formule (I) kao što je definiran u bilo kojem od prethodnih zahtjeva 1 do 7, naznačen time, da se upotrebljava u liječenju bolesti koje su bazirane na ekspresiji CX3CR1 i p40, a odabrane su iz skupine koju čine dijabetska nefropatija, Crohnova bolest, ulcerativni kolitis, koronarni poremećaji, restenoza, infarkt miokarda, angina, lupus eritematoza, psorijaza i dijabetes tipa II.
HRP20171208TT 2008-03-07 2017-08-07 Novi derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti koje se baziraju na ekspresiji cx3cr1 i p40 HRP20171208T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08425139 2008-03-07
EP09717638.2A EP2254869B1 (en) 2008-03-07 2009-03-05 Neue 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of cx3cr1 und p40
PCT/EP2009/052585 WO2009109613A2 (en) 2008-03-07 2009-03-05 Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40

Publications (1)

Publication Number Publication Date
HRP20171208T1 true HRP20171208T1 (hr) 2017-10-06

Family

ID=39671487

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20160462TT HRP20160462T1 (hr) 2008-03-07 2016-05-02 Derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti baziranih na ekspresiji mcp-1, cx3cr1
HRP20171208TT HRP20171208T1 (hr) 2008-03-07 2017-08-07 Novi derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti koje se baziraju na ekspresiji cx3cr1 i p40

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HRP20160462TT HRP20160462T1 (hr) 2008-03-07 2016-05-02 Derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti baziranih na ekspresiji mcp-1, cx3cr1

Country Status (25)

Country Link
US (3) US7919518B2 (hr)
EP (3) EP2254870B1 (hr)
JP (2) JP5509101B2 (hr)
KR (2) KR101599867B1 (hr)
CN (2) CN101945855B (hr)
AR (2) AR070810A1 (hr)
AU (2) AU2009221083B2 (hr)
BR (2) BRPI0907976A2 (hr)
CA (2) CA2712703C (hr)
CY (2) CY1117584T1 (hr)
DK (2) DK2254870T3 (hr)
EA (2) EA018241B1 (hr)
ES (2) ES2569330T3 (hr)
GE (2) GEP20135983B (hr)
HR (2) HRP20160462T1 (hr)
HU (1) HUE027098T2 (hr)
IL (3) IL206893A0 (hr)
LT (1) LT2254869T (hr)
MX (2) MX2010009626A (hr)
PL (2) PL2254870T3 (hr)
PT (1) PT2254869T (hr)
SG (1) SG188177A1 (hr)
SI (2) SI2254869T1 (hr)
UA (2) UA105170C2 (hr)
WO (2) WO2009109618A2 (hr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8314099B2 (en) 2008-03-07 2012-11-20 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1 and CX3CR1
MX2010009626A (es) * 2008-03-07 2010-12-20 Acraf Derivados de 1-bencil-3-hidroximetilindazol y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1.
BRPI0907974A2 (pt) 2008-03-07 2015-08-04 Acraf Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças
EP2462118B1 (en) * 2009-08-03 2014-06-11 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Process for the preparation of 1-benzyl-3-hydroxymethyl-1H-indazole and its derivatives and required Magnesium intermediates
UA108742C2 (uk) * 2009-09-23 2015-06-10 Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
CA3095012C (en) * 2012-05-01 2023-02-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
US9346762B2 (en) * 2012-05-18 2016-05-24 Sanofi Pyrazole derivatives and their use as LPAR5 antagonists
WO2013171316A1 (en) 2012-05-18 2013-11-21 Sanofi Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
WO2014074854A1 (en) 2012-11-09 2014-05-15 Wang Tongxin Block copolymers for tooth enamel protection
ES2789849T3 (es) * 2014-05-15 2020-10-26 Translatum Medicus Inc Composiciones y procedimientos para el tratamiento y diagnóstico de trastornos oculares
EP3942934A1 (en) * 2015-06-12 2022-01-26 Vettore, LLC Mct4 inhibitors for treating disease
EP3310353A4 (en) * 2015-06-16 2019-02-06 Translatum Medicus, Inc. COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF EYE DISEASES
CA3046212A1 (en) 2016-12-12 2018-06-21 Vettore, LLC Heterocyclic inhibitors of mct4
GB201811169D0 (en) 2018-07-06 2018-08-29 Kancera Ab New compounds
JP6612004B1 (ja) * 2018-07-31 2019-11-27 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
WO2020026471A1 (ja) * 2018-07-31 2020-02-06 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
WO2020261158A1 (en) * 2019-06-25 2020-12-30 Translatum Medicus Inc. Processes of making 2-((1-benzyl-1h-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives
CN113929627A (zh) * 2021-10-19 2022-01-14 吕梁学院 一种宾达利的合成方法
WO2024108386A1 (zh) * 2022-11-22 2024-05-30 中国科学院深圳先进技术研究院 抗mcp1中和抗体在制备治疗神经退行性疾病引起的系统性炎症药物中的应用
WO2024165925A1 (en) * 2023-02-10 2024-08-15 Translatum Medicus Inc. Bindarit conjugates, compositions and methods for treating ocular diseases or disorders

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US416359A (en) * 1889-12-03 Sash-fastener
US364371A (en) * 1887-06-07 peice
IT1230441B (it) * 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
IT1293795B1 (it) * 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
AU781849C (en) 1999-06-17 2006-03-02 Synta Pharmaceuticals Corp. Inhibitors of IL-12 production
EP1188438A1 (en) 2000-09-15 2002-03-20 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production
EP1199074A1 (en) 2000-09-15 2002-04-24 Warner-Lambert Company Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production
WO2002074318A1 (fr) 2001-03-15 2002-09-26 Seikagaku Corporation Agents de regulation d'expression d'il-12
CN100349876C (zh) 2001-11-30 2007-11-21 辛塔医药品有限公司 嘧啶化合物
EP1675862A1 (en) 2003-10-07 2006-07-05 AstraZeneca AB New 2-substituted, 4-amino-thiazolo 4,5-d pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1
ES2641815T3 (es) * 2004-10-29 2017-11-14 Eisai R&D Management Co., Ltd. Tratamiento para enfermedades inflamatorias
AU2005304393B2 (en) 2004-11-10 2012-09-27 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
JP2008520712A (ja) 2004-11-19 2008-06-19 シンタ ファーマシューティカルズ コーポレーション ピリミジン化合物及びその使用
UA90707C2 (en) 2005-04-06 2010-05-25 Астразенека Аб Novel 5-substituted 7-amino-[1,3]thiazolo[4,5-d]pyrimidine derivatives
AR053347A1 (es) 2005-04-06 2007-05-02 Astrazeneca Ab Derivados de [1,3]tiazolo[4,5-d]pirimidin-2(3h)-ona 5,7-sustituidos
US8314099B2 (en) 2008-03-07 2012-11-20 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of MCP-1 and CX3CR1
MX2010009626A (es) 2008-03-07 2010-12-20 Acraf Derivados de 1-bencil-3-hidroximetilindazol y su uso en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1.
BRPI0907974A2 (pt) 2008-03-07 2015-08-04 Acraf Composto, composição farmacêutica, uso de um composto, e, método para tratar ou prevenir doenças

Also Published As

Publication number Publication date
EP2254870B1 (en) 2016-02-24
DK2254870T3 (en) 2016-05-17
GEP20135983B (en) 2013-12-10
EP3181551A1 (en) 2017-06-21
SI2254869T1 (sl) 2017-10-30
US20100311744A1 (en) 2010-12-09
CN101945855A (zh) 2011-01-12
CA2712403C (en) 2017-06-06
IL206893A0 (en) 2010-12-30
CA2712703A1 (en) 2009-09-11
AU2009221083A1 (en) 2009-09-11
MX2010009626A (es) 2010-12-20
ES2569330T3 (es) 2016-05-10
PL2254870T3 (pl) 2016-07-29
WO2009109613A2 (en) 2009-09-11
BRPI0907977A2 (pt) 2015-08-04
AU2009221083B2 (en) 2013-11-28
HRP20160462T1 (hr) 2016-06-03
IL207131A (en) 2013-02-28
SI2254870T1 (sl) 2016-05-31
WO2009109618A3 (en) 2009-12-10
AU2009221089B2 (en) 2013-12-05
JP2011513367A (ja) 2011-04-28
US7919518B2 (en) 2011-04-05
GEP20135912B (en) 2013-08-26
WO2009109618A2 (en) 2009-09-11
KR20100133957A (ko) 2010-12-22
EA018241B1 (ru) 2013-06-28
EP2254869B1 (en) 2017-05-31
IL207131A0 (en) 2010-12-30
KR101581828B1 (ko) 2015-12-31
US8835481B2 (en) 2014-09-16
AR070811A1 (es) 2010-05-05
IL215579A (en) 2015-06-30
EA201071040A1 (ru) 2011-02-28
ES2637009T3 (es) 2017-10-10
AR070810A1 (es) 2010-05-05
EA201071038A1 (ru) 2011-02-28
CN101945855B (zh) 2014-12-17
DK2254869T3 (en) 2017-09-04
WO2009109613A3 (en) 2009-12-10
US8283348B2 (en) 2012-10-09
PL2254869T3 (pl) 2017-10-31
MX2010009623A (es) 2010-09-28
CN101952256A (zh) 2011-01-19
CA2712703C (en) 2016-10-11
EA019711B1 (ru) 2014-05-30
CA2712403A1 (en) 2009-09-11
BRPI0907976A2 (pt) 2015-08-04
UA105170C2 (en) 2014-04-25
CY1117584T1 (el) 2017-04-26
JP5509101B2 (ja) 2014-06-04
CY1119252T1 (el) 2018-02-14
IL215579A0 (en) 2011-11-30
AU2009221089A1 (en) 2009-09-11
JP2011513365A (ja) 2011-04-28
US20110160205A1 (en) 2011-06-30
SG188177A1 (en) 2013-03-28
EP2254870A2 (en) 2010-12-01
UA103605C2 (en) 2013-11-11
JP5509099B2 (ja) 2014-06-04
PT2254869T (pt) 2017-07-18
KR20100131432A (ko) 2010-12-15
KR101599867B1 (ko) 2016-03-04
US20110003874A1 (en) 2011-01-06
EP2254869A2 (en) 2010-12-01
LT2254869T (lt) 2017-08-10
HUE027098T2 (en) 2016-08-29
CN101952256B (zh) 2016-03-16

Similar Documents

Publication Publication Date Title
HRP20171208T1 (hr) Novi derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti koje se baziraju na ekspresiji cx3cr1 i p40
HRP20191953T1 (hr) DERIVATI 1-BENZIL-3-HIDROKSIMETILINDAZOLA I NJIHOVA UPORABA U LIJEČENJU BOLESTI KOJE SE BAZIRAJU NA EKSPRESIJI MCP-1, CXCR1 i p40
HRP20160457T1 (hr) Derivati 1-benzil-3-hidroksimetilindazola i njihova uporaba u liječenju bolesti baziranih na ekspresiji mcp-1 i cx3cr1
PE20220143A1 (es) Agonistas de glp-1r y usos de los mismos
NZ788543A (en) Dimethyltryptamine derivatives and their use in psychedelic-assisted psychotherapy
HRP20170695T1 (hr) Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka
NO20065613L (no) 3-karbamoyl-2-pyridonderivat.
HRP20151078T1 (hr) Pirazoli kao 11-beta-hsd-1
HRP20130900T1 (hr) Derivat (aza)indola i njegova uporaba u medicinske svrhe
HRP20211762T1 (hr) Derivati benzoksaborola za liječenje bakterijskih infekcija
ME01089B (me) Derivat benzimidazola i njegova upotreba kao antagonista receptora aii
HRP20141199T1 (hr) Kombinacija od spoja glyt1 s antipsihoticima
ME01564B (me) Adicione soli amina koji sadrže hidroksilne i/ ili karboksilne grupe s derivatima aminonikotinske kiseline kao dhodh inhibitorima
SV2011003912A (es) Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1
GT200400174A (es) Compuestos de bencimidazolona que tienen actividad agonista del receptor 5 ht4
ECSP077185A (es) Derivados de piridina
PT2420491E (pt) Compostos de piperidina 3,5-substituída como inibidores de renina
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
CA2679198A1 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
MA29775B1 (fr) Derives de pyrazolone
TW200603797A (en) Substituted 4-alkyl- and 4-alkanoyl-piperidine derivatives and their use as neurokinin antagonists
MA32108B1 (fr) Derives d'indazole
NO20073250L (no) Non-anilinderivater av isotiazol-3- (2H)-on 1,1-dioksider som lever-X-reseptor modulerende forbindelser.
MX2010001082A (es) Composicion farmaceutica que contiene compuesto opticamente activo que tiene actividad agonista del receptor de trombopoyetina y compuesto intermedio para el mismo.
CA2559530A1 (en) Novel benzyl(idene)-lactam derivatives